Citadel Advisors
SPRB

Citadel Advisors’s Spruce Biosciences SPRB Stock Holding History

Citadel Advisors’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.8M Sell
51,905
-18,094
-26% -$1.01M ﹤0.01% 5819
2026
Q1 		$4.57M Hold
69,999
– – ﹤0.01% 4491
2025
Q4 		$6.1M Buy
+69,999
New +$7.5M ﹤0.01% 3973
2024
Q4 		– Sell
-1,027
Closed -$36.6K – 15612
2024
Q3 		$36.6K Sell
1,027
-103
-9% -$3.77K ﹤0.01% 12245
2024
Q2 		$43.9K Sell
1,130
-42
-4% -$2.25K ﹤0.01% 11909
2024
Q1 		$69.1K Sell
1,172
-271
-19% -$68.9K ﹤0.01% 11830
2023
Q4 		$317K Buy
1,443
+443
+44% +$51.2K ﹤0.01% 9053
2023
Q3 		$170K Buy
1,000
+50
+5% +$8.43K ﹤0.01% 10165
2023
Q2 		$153K Sell
950
-21,698
-96% -$3.63M ﹤0.01% 10307
2023
Q1 		$3.75M Sell
22,648
-651
-3% -$121K ﹤0.01% 4283
2022
Q4 		$1.92M Buy
23,299
+238
+1% +$19.9K ﹤0.01% 5558
2022
Q3 		$2.37M Buy
23,061
+68
+0.3% +$9.5K ﹤0.01% 5267
2022
Q2 		$3M Buy
22,993
+35
+0.2% +$4.48K ﹤0.01% 4755
2022
Q1 		$3.46M Sell
22,958
-70
-0.3% -$13K ﹤0.01% 4890
2021
Q4 		$7.7M Buy
23,028
+347
+2% +$103K ﹤0.01% 3527
2021
Q3 		$10.2M Sell
22,681
-26
-0.1% -$16.3K ﹤0.01% 3037
2021
Q2 		$19.1M Buy
22,707
+3
+0% +$3.2K ﹤0.01% 2147
2021
Q1 		$28.3M Buy
22,704
+14
+0.1% +$21.5K 0.01% 1580
2020
Q4 		$41.4M Buy
+22,690
New +$37.6M 0.01% 1104

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Citadel Advisors's SPRB Position: Q2 2026 in Review

Citadel Advisors reduced its Spruce Biosciences (SPRB) stake by 26% in Q2 2026, selling an estimated $1.01M and leaving 51,905 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #5819.

Citadel Advisors first reported a position in SPRB in Q4 2020 and has held it in 19 quarters since. The position peaked at $41.4M in Q4 2020. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Citadel Advisors held 51,905 shares of Spruce Biosciences worth $2.8M as of Q2 2026.
  • Citadel Advisors sold 18,094 Spruce Biosciences shares in Q2 2026, an estimated $1.01M.
  • Spruce Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5819 holding.
  • Citadel Advisors first reported a position in Spruce Biosciences in Q4 2020 and has held it in 19 quarters since.
  • Citadel Advisors's Spruce Biosciences position peaked at $41.4M in Q4 2020.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.